
BBNX Stock Forecast & Price Target
BBNX Analyst Ratings
Bulls say
Beta Bionics is on track with its expansion in the U.S. pharmacy channel, which could potentially drive significant revenue upside over a multi-year period and also increase gross margins through 2026. The warning letter is unlikely to have any material impact on the company's day-to-day operations or new product launches, and its recent WL was primarily related to quality system issues, which management stated are already being addressed and should not hinder the company's future growth prospects. The launch of the company's Mint patch pump in 2027 could be a significant catalyst for the company, and we view its current valuation as attractive given its growth potential and strong financial performance.
Bears say
Beta Bionics is showing promising innovation with its iLet Bionic Pancreas and expanding sales force, but its negative headlines, including a recent FDA Warning Letter and a pre-announced NPS miss, have caused the stock to decline (-55% YTD). The company's goal of disrupting the diabetes market and strong CAGR prospects are favorable, but uncertainty surrounding the pace of NPS momentum and the execution of the patch pump launch suggest a cautious approach to investing in this volatile stock.
This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.
BBNX Analyst Forecast & Price Prediction
Start investing in BBNX
Order type
Buy in
Order amount
Est. shares
0 shares